search
Back to results

Exercise Following Bariatric Surgery for Severe/Morbid Obesity (EFIBAR) (EFIBAR)

Primary Purpose

Obesity, Morbid, Bariatric Surgery Candidate

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Exercise
Sponsored by
Universidad de Almeria
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity, Morbid focused on measuring Morbid obesity, Exercise, Weight loss, Cardiometabolic risk, Bariatric surgery

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • To comply with local bariatric surgery criteria:

    1. Patients with BMI ≥ 40 kg/m2 (or 35 kg/m2 with comorbidities).
    2. Acceptable surgical risk (defined by the approval of anesthetist).
    3. Obesity maintained for over 5 years.
    4. Failure of previous treatments.
    5. To sign informed consent for surgical treatment.
  • Not to present contraindications for supervised physical exercise.
  • To reside in the city of Almeria (Spain) or willingness/predisposition to attend the training sessions 3 times a week during 16 weeks

Exclusion Criteria:

  • Severe psychiatric or neurological disorders such as schizophrenia, epilepsia, Alzheimer, Parkinson, personality disorders, eating behaviour disorders, untreated depression or suicidal tendencies.
  • Adrenal or thyroid pathology that might cause obesity.
  • Uncontrolled addiction to alcohol or drugs.

Sites / Locations

  • Complejo Hospitalario Torrecárdenas (CHT)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Exercise

Control

Arm Description

Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.

Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.

Outcomes

Primary Outcome Measures

Percent total weight loss (%TWL) [Biospace Co., InBody 270, USA]
%TWL = [(pre-surgery weight - post-surgery weight) / (pre-surgery weight)] x 100

Secondary Outcome Measures

Body composition: body fat
Percent body fat (%) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Body composition: fat-free mass
Fat-free mass (kg) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Body composition: fat-free mass index
Fat-free mass index (kg/m2) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Body composition: central body fat
Waist and hip circumferences (measured in cm with an anthropometric tape), waist / height ratio
Lipid profile assessed from blood sample
Total cholesterol (mg/dl), HDL-cholesterol (mg/dl), LDL-cholesterol (mg/dl) and triglycerides (mg/dl)
Blood markers of glucose metabolism: glucose
Glucose (mg/dL)
Blood markers of glucose metabolism: insulin
Insulin (μUI/mL)
Blood markers of glucose metabolism: HOMA-IR
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Blood markers of glucose metabolism: glycated hemoglobin HbA1c
Glycated hemoglobin HbA1c (%)
Brachial and central blood pressures (mmHg)
Systolic and diastolic blood pressures assessed by Mobil-O-Graph
Arterial stiffness
Pulse wave velocity (PWV, m/s) by Mobil-O-Graph
Plasma concentrations of inflammatory markers
High-sensitivity C-reactive protein (hs-CRP)
Plasma concentrations of inflammatory markers
Tumor necrosis factor (TNF-alpha)
Plasma concentrations of inflammatory markers
Interleukin 6 (IL-6)
Plasma concentrations of liver metabolism enzymes
GGT (gamma-glutamyltransferase)
Plasma concentrations of liver metabolism enzymes
GPT (glutamate-pyruvate transaminase)
Plasma concentrations of liver metabolism enzymes
GOT (glutamate-oxalacetate transaminase)
Plasma levels of Vitamin D
Concentrations of 25-hydroxyvitamin D (ng/mL)
Heart rate variability (HRV)
Assessed by heart rate monitor (Polar V800)
Health-related physical fitness: cardiorespiratory fitness
Cardiorespiratory fitness, assessed using a maximal treadmill test
Health-related physical fitness: upper body muscular strength
Upper body muscular strength, assessed using handgrip dynamometry (kg)
Health-related physical fitness: lower body muscular strength
Lower body muscular strength, assessed using the 30-seconds chair-stand test (number of repetitions)
Health-related physical fitness: upper body flexibility
Upper body flexibility, assessed using the back scratch test (cm)
Objectively-measured physical activity
Assessed by accelerometry (ActiGraph, software ActiLife)
Health-Related Quality of Life (HRQoL): SF-36
Measured by the 36-item Short Form Health Survey (SF-36)
Health-Related Quality of Life (HRQoL): EQ-5D-3L
Measured by European Quality of Life - 5 Dimensions-3Levels (EQ-5D-3L)
Symptomatology and function of hip / knee osteoarthritis: Pain
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The PAIN scale within the WOMAC questionnaire contains 5 items, each one scoring from 0 (Nothing) to 4 (Very much), what makes a total score ranging from 0 (better) to 20 (worse).
Symptomatology and function of hip / knee osteoarthritis: Function
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The FUNCTION scale within the WOMAC questionnaire contains 17 items, each one scoring from 0 (No trouble) to 4 (Very much difficult), what makes a total score ranging from 0 (better) to 68 (worse).
Symptomatology and function of hip / knee osteoarthritis: Stiffness
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The STIFFNESS scale within the WOMAC questionnaire contains 2 items, each one scoring from 0 (Nothing) to 4 (Very much), what makes a total score ranging from 0 (better) to 8 (worse).
Depression, anxiety and stress
Measured by the Depression, Anxiety and Stress Scale short form (DASS-21). The DASS-21 comprises three sub-scales assessing specific psychiatric symptoms (i.e., depression, anxiety, and stress). Each of these symptoms is assessed using seven items rated on a 4-point Likert-type scale (i.e., 0 = ''Did not apply to me at all''; 3 = ''Applied to me very much, or most of the time''). Summed score for each psychiatric symptom ranges from 0 to 21. Higher scores in each sub-scale indicate higher levels of depressive, anxiety or stress symptomatology. According to the specific nature of the three psychiatric symptoms assessed by the DASS-21, these are treated independently so that no total score is available.
Emotional, psychological and social well-being
Measured by the Mental Health Continuum-Short Form (MHC-SF)
Cost-effectiveness analysis (CEA)
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Effectiveness will be considered as changes observed in the main clinical outcomes: weight loss and cardiometabolic risk (remission/relapse of hypertension, dyslipidemia and type 2 diabetes).
Cost-utility analysis (CUA)
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Utility will evaluate variation in quality of life experienced by participants, computed as changes in quality-adjusted life years (QALY) using SF-36 questionnaire.
Cost-utility analysis (CUA)
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Utility will evaluate variation in quality of life experienced by participants, computed as changes in quality-adjusted life years (QALY) using EQ-5D-3L questionnaire.

Full Information

First Posted
March 7, 2018
Last Updated
September 4, 2023
Sponsor
Universidad de Almeria
Collaborators
Ministerio de Economía y Competitividad, Spain, Complejo Hospitalario Torrecárdenas (CHT), Almería, Spain
search

1. Study Identification

Unique Protocol Identification Number
NCT03497546
Brief Title
Exercise Following Bariatric Surgery for Severe/Morbid Obesity (EFIBAR)
Acronym
EFIBAR
Official Title
Supervised Exercise Following Bariatric Surgery in the Treatment of Severe/Morbid Obesity: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
September 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad de Almeria
Collaborators
Ministerio de Economía y Competitividad, Spain, Complejo Hospitalario Torrecárdenas (CHT), Almería, Spain

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Severe/morbid obesity is an international public health issue that importantly increases the risk of cardiovascular events and cardiovascular and all-cause mortality. Likewise, severe/morbid obesity increases the risk of illness, reduces quality of life, and raises health-care costs. Bariatric surgery is the election method for the treatment of severe/morbid obesity, resulting in significant weight loss and remission of comorbidities. However, a relatively large proportion of bariatric patients regain weight and continue to be at high risk for cardiovascular disease and premature mortality. A healthy lifestyle following bariatric surgery is essential for optimizing and maintaining weight loss. Observational studies suggest that physical activity following bariatric surgery might be associated with additional weight loss and more effective weigh loss maintenance over time. However, very little experimental evidence exists regarding the effects of supervised exercise on obesity-related outcomes in this specific population. The aim of the EFIBAR (Ejercicio FÍsico tras cirugía BARiátrica) randomized controlled trial is to determine the effects of a 16-week supervised concurrent (aerobic and strength) exercise intervention program, on weight loss (primary outcome), body composition, cardiometabolic risk, physical fitness and quality of life (secondary outcomes) in patients with severe/morbid obesity following bariatric surgery. According to the study aims the investigators pursue the following hypothesis: Supervised exercise will result in larger weight loss than control.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Morbid, Bariatric Surgery Candidate
Keywords
Morbid obesity, Exercise, Weight loss, Cardiometabolic risk, Bariatric surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Eligible participants will be randomly assigned (1:1) sequentially, as they will be submitted to bariatric surgery, to one of the two following groups: CON - Usual care (following international guidelines) after bariatric surgery. EX - Usual care plus supervised exercise program.
Masking
InvestigatorOutcomes Assessor
Masking Description
Investigators, study coordinators, outcome assessors, and clinical staff will be blinded to the group allocation. Participants and providers of the exercise delivery will not be blinded to the group allocation.
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercise
Arm Type
Experimental
Arm Description
Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.
Intervention Type
Other
Intervention Name(s)
Exercise
Other Intervention Name(s)
Exercise training
Intervention Description
Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
Primary Outcome Measure Information:
Title
Percent total weight loss (%TWL) [Biospace Co., InBody 270, USA]
Description
%TWL = [(pre-surgery weight - post-surgery weight) / (pre-surgery weight)] x 100
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Secondary Outcome Measure Information:
Title
Body composition: body fat
Description
Percent body fat (%) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Body composition: fat-free mass
Description
Fat-free mass (kg) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Body composition: fat-free mass index
Description
Fat-free mass index (kg/m2) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Body composition: central body fat
Description
Waist and hip circumferences (measured in cm with an anthropometric tape), waist / height ratio
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Lipid profile assessed from blood sample
Description
Total cholesterol (mg/dl), HDL-cholesterol (mg/dl), LDL-cholesterol (mg/dl) and triglycerides (mg/dl)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Blood markers of glucose metabolism: glucose
Description
Glucose (mg/dL)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Blood markers of glucose metabolism: insulin
Description
Insulin (μUI/mL)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Blood markers of glucose metabolism: HOMA-IR
Description
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Blood markers of glucose metabolism: glycated hemoglobin HbA1c
Description
Glycated hemoglobin HbA1c (%)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Brachial and central blood pressures (mmHg)
Description
Systolic and diastolic blood pressures assessed by Mobil-O-Graph
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Arterial stiffness
Description
Pulse wave velocity (PWV, m/s) by Mobil-O-Graph
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Plasma concentrations of inflammatory markers
Description
High-sensitivity C-reactive protein (hs-CRP)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Plasma concentrations of inflammatory markers
Description
Tumor necrosis factor (TNF-alpha)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Plasma concentrations of inflammatory markers
Description
Interleukin 6 (IL-6)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Plasma concentrations of liver metabolism enzymes
Description
GGT (gamma-glutamyltransferase)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Plasma concentrations of liver metabolism enzymes
Description
GPT (glutamate-pyruvate transaminase)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Plasma concentrations of liver metabolism enzymes
Description
GOT (glutamate-oxalacetate transaminase)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Plasma levels of Vitamin D
Description
Concentrations of 25-hydroxyvitamin D (ng/mL)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Heart rate variability (HRV)
Description
Assessed by heart rate monitor (Polar V800)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Health-related physical fitness: cardiorespiratory fitness
Description
Cardiorespiratory fitness, assessed using a maximal treadmill test
Time Frame
Changes from baseline to 4-month and and 1-year follow-up
Title
Health-related physical fitness: upper body muscular strength
Description
Upper body muscular strength, assessed using handgrip dynamometry (kg)
Time Frame
Changes from baseline to 4-month and and 1-year follow-up
Title
Health-related physical fitness: lower body muscular strength
Description
Lower body muscular strength, assessed using the 30-seconds chair-stand test (number of repetitions)
Time Frame
Changes from baseline to 4-month and and 1-year follow-up
Title
Health-related physical fitness: upper body flexibility
Description
Upper body flexibility, assessed using the back scratch test (cm)
Time Frame
Changes from baseline to 4-month and and 1-year follow-up
Title
Objectively-measured physical activity
Description
Assessed by accelerometry (ActiGraph, software ActiLife)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Health-Related Quality of Life (HRQoL): SF-36
Description
Measured by the 36-item Short Form Health Survey (SF-36)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Health-Related Quality of Life (HRQoL): EQ-5D-3L
Description
Measured by European Quality of Life - 5 Dimensions-3Levels (EQ-5D-3L)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Symptomatology and function of hip / knee osteoarthritis: Pain
Description
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The PAIN scale within the WOMAC questionnaire contains 5 items, each one scoring from 0 (Nothing) to 4 (Very much), what makes a total score ranging from 0 (better) to 20 (worse).
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Symptomatology and function of hip / knee osteoarthritis: Function
Description
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The FUNCTION scale within the WOMAC questionnaire contains 17 items, each one scoring from 0 (No trouble) to 4 (Very much difficult), what makes a total score ranging from 0 (better) to 68 (worse).
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Symptomatology and function of hip / knee osteoarthritis: Stiffness
Description
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The STIFFNESS scale within the WOMAC questionnaire contains 2 items, each one scoring from 0 (Nothing) to 4 (Very much), what makes a total score ranging from 0 (better) to 8 (worse).
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Depression, anxiety and stress
Description
Measured by the Depression, Anxiety and Stress Scale short form (DASS-21). The DASS-21 comprises three sub-scales assessing specific psychiatric symptoms (i.e., depression, anxiety, and stress). Each of these symptoms is assessed using seven items rated on a 4-point Likert-type scale (i.e., 0 = ''Did not apply to me at all''; 3 = ''Applied to me very much, or most of the time''). Summed score for each psychiatric symptom ranges from 0 to 21. Higher scores in each sub-scale indicate higher levels of depressive, anxiety or stress symptomatology. According to the specific nature of the three psychiatric symptoms assessed by the DASS-21, these are treated independently so that no total score is available.
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Emotional, psychological and social well-being
Description
Measured by the Mental Health Continuum-Short Form (MHC-SF)
Time Frame
Changes from baseline to 4-month and 1-year follow-up
Title
Cost-effectiveness analysis (CEA)
Description
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Effectiveness will be considered as changes observed in the main clinical outcomes: weight loss and cardiometabolic risk (remission/relapse of hypertension, dyslipidemia and type 2 diabetes).
Time Frame
From baseline to 1-year follow-up
Title
Cost-utility analysis (CUA)
Description
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Utility will evaluate variation in quality of life experienced by participants, computed as changes in quality-adjusted life years (QALY) using SF-36 questionnaire.
Time Frame
From baseline to 1-year follow-up
Title
Cost-utility analysis (CUA)
Description
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Utility will evaluate variation in quality of life experienced by participants, computed as changes in quality-adjusted life years (QALY) using EQ-5D-3L questionnaire.
Time Frame
From baseline to 1-year follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: To comply with local bariatric surgery criteria: Patients with BMI ≥ 40 kg/m2 (or 35 kg/m2 with comorbidities). Acceptable surgical risk (defined by the approval of anesthetist). Obesity maintained for over 5 years. Failure of previous treatments. To sign informed consent for surgical treatment. Not to present contraindications for supervised physical exercise. To reside in the city of Almeria (Spain) or willingness/predisposition to attend the training sessions 3 times a week during 16 weeks Exclusion Criteria: Severe psychiatric or neurological disorders such as schizophrenia, epilepsia, Alzheimer, Parkinson, personality disorders, eating behaviour disorders, untreated depression or suicidal tendencies. Adrenal or thyroid pathology that might cause obesity. Uncontrolled addiction to alcohol or drugs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enrique G Artero, Ph.D.
Organizational Affiliation
Universidad de Almeria
Official's Role
Principal Investigator
Facility Information:
Facility Name
Complejo Hospitalario Torrecárdenas (CHT)
City
Almería
ZIP/Postal Code
04009
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All IPD will be shared once the study is finalised and the main results are published. IPD can be obtained by contacting the responsible party (artero@ual.es).
IPD Sharing Time Frame
Two years (24 months) after the study completion.
IPD Sharing Access Criteria
The PI must be contacted and a minimum number of co-authors from the research team must be included in any publication.
Citations:
PubMed Identifier
31488115
Citation
Villa-Gonzalez E, Barranco-Ruiz Y, Rodriguez-Perez MA, Carretero-Ruiz A, Garcia-Martinez JM, Hernandez-Martinez A, Torrente-Sanchez MJ, Ferrer-Marquez M, Soriano-Maldonado A, Artero EG; EFIBAR Study Group. Supervised exercise following bariatric surgery in morbid obese adults: CERT-based exercise study protocol of the EFIBAR randomised controlled trial. BMC Surg. 2019 Sep 5;19(1):127. doi: 10.1186/s12893-019-0566-9.
Results Reference
background
PubMed Identifier
34268680
Citation
Artero EG, Ferrez-Marquez M, Torrente-Sanchez MJ, Martinez-Rosales E, Carretero-Ruiz A, Hernandez-Martinez A, Lopez-Sanchez L, Esteban-Simon A, Romero Del Rey A, Alcaraz-Ibanez M, Rodriguez-Perez MA, Villa-Gonzalez E, Barranco-Ruiz Y, Martinez-Forte S, Castillo C, Gomez Navarro C, Aceituno Cubero J, Reyes Parrilla R, Aparicio Gomez JA, Femia P, Fernandez-Alonso AM, Soriano-Maldonado A. Supervised Exercise Immediately After Bariatric Surgery: the Study Protocol of the EFIBAR Randomized Controlled Trial. Obes Surg. 2021 Oct;31(10):4227-4235. doi: 10.1007/s11695-021-05559-8. Epub 2021 Jul 15.
Results Reference
background
Links:
URL
https://link.springer.com/article/10.1007/s11695-021-05559-8
Description
Study Protocol of the EFIBAR Randomized Controlled Trial
URL
https://bmcsurg.biomedcentral.com/articles/10.1186/s12893-019-0566-9
Description
CERT-based exercise study protocol of the EFIBAR randomised controlled trial

Learn more about this trial

Exercise Following Bariatric Surgery for Severe/Morbid Obesity (EFIBAR)

We'll reach out to this number within 24 hrs